By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...

A groundbreaking multi-stakeholder report reveals that transitioning to Non-Animal Methods (NAMs) can reduce drug development ...

As India’s pharmaceutical industry moves towards becoming a 500 billion dollars global powerhouse by 2047, a new report ...

In a year from now, progress is to be measured in the institutionalisation of the approach with greater regulatory acceptance ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

A major step towards simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to ...

New treatments based on biological molecules like RNA give scientists unprecedented control over how cells function. But ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...

The report compares India’s non-clinical drug approval framework with regulatory practices in the US, European Union, the UK ...